Publication: Progress in the Management of Malignant Pleural Mesothelioma in 2017
Issued Date
2018-05-01
Resource Type
ISSN
15561380
15560864
15560864
Other identifier(s)
2-s2.0-85046378485
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Thoracic Oncology. Vol.13, No.5 (2018), 606-623
Suggested Citation
Amanda J. McCambridge, Andrea Napolitano, Aaron S. Mansfield, Dean A. Fennell, Yoshitaka Sekido, Anna K. Nowak, Thanyanan Reungwetwattana, Weimin Mao, Harvey I. Pass, Michele Carbone, Haining Yang, Tobias Peikert Progress in the Management of Malignant Pleural Mesothelioma in 2017. Journal of Thoracic Oncology. Vol.13, No.5 (2018), 606-623. doi:10.1016/j.jtho.2018.02.021 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46739
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Other Contributor(s)
Zhejiang Cancer Hospital
University of Leicester
Università degli Studi di Roma La Sapienza
NYU Langone Medical Center
University of Western Australia
Aichi Cancer Center Hospital and Research Institute
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
University of Hawaii at Manoa
Mayo Clinic
Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology
University of Leicester
Università degli Studi di Roma La Sapienza
NYU Langone Medical Center
University of Western Australia
Aichi Cancer Center Hospital and Research Institute
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
University of Hawaii at Manoa
Mayo Clinic
Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology
Abstract
© 2018 International Association for the Study of Lung Cancer Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.